A R T I C L E S
Liao et al.
binding profile12-17 and by dissecting the binding energy
contribution via quantitative analysis.17 This new tool may
provide an alternative approach to the current methods based
on RT-PCR (which is highly accurate but time-consuming)18
and ELISA based on antibody-nucleoprotein interaction (which
is quick but less accurate).19 A recent significant discovery by
using glycan array is that Tumpey’s group examined the glycan
binding properties of the 2009 A(H1N1) HA and found that
the soluble form of CA/04 HA exhibited specific preference to
longer R2,6 glycan (6’SLN-LN) structures. This binding
behavior showed a significant difference from seasonal influenza
H1N1 viral HA.15 Moreover, Feizi’s group also utilized a glycan
array to evaluate the binding specificity of different influenza
viruses and found that Cal/09 and Ham/09 H1N1 viruses bound
not only to the R2,6-linked sialosides but also to a considerable
range of the R2,3-linked sialyl sequences, and Mem/96 bound
exclusively to the R2,6-linked sequences.16
site and study their secondary structure and receptor binding
using circular dichroism and a designer synthetic glycan array.
Results and Discussion
Preparation of Sialosides Array for HA Binding Evaluation.
In naturally occurring sialosides, Neu5Ac is linked to other
sugars through an R-linkage. For example, Neu5Ac is commonly
found as a terminal sugar linked to galactosides through the
R2,3 or R2,6 linkage in both N-linked and O-linked glycopro-
teins and also to N-acetyl-galactosamine through the R2,6
linkage in O-linked glycoproteins. In addition, Neu5Ac can be
linked to another Neu5Ac residue via the R2,8 or R2,9 linkage
as a constituent of glycoproteins and glycolipids.22,23 Though
enzymatic sialylation provides R-linked sialosides stereospe-
cifically, the enzymes are not all readily available and are often
limited to, though with some exceptions, the synthesis of
naturally occurring sialosides due to their substrate specificity.24,25
This limitation precludes the synthesis of a wide range of
sialosdies. We have therefore developed an R-specific sialylation
donor (D) for the synthesis of various R-sialosides, including
the design of “sialylated disaccharide” as building blocks for
the one-pot synthesis of sialylated oligosaccharides.26 We have
further extended this strategy to the preparation of a sialoside
array. By using disaccharide A27-29 as building block, seventeen
R2,3-linked sialosides (1-17) of disaccharides to hexasaccharide
were synthesized, and, using the disaccharide B as building
block, several R2,6-linked sialosides (21-30) were prepared
(Table S1 and Schemes S2-S13 of the Supporting Information).
These glycans were spotted onto the NHS-activated glass slide
via amide bond formation12 to create an array of sialosides for
HA binding evaluation.
In contrast to the well-known binding preferences of various
HA subtypes, the effect of HA glycosylation on receptor binding
is still not well understood. The addition and processing of
N-linked oligosaccharides on a protein has been shown to be
important in maintaining protein conformation and stability and
in modulating biological activities.20 In addition, glycosylation
may protect proteins from clearance and proteolysis. In the case
of virus glycoproteins, glycans may also protect the virus from
immune attacks and modulate receptor recognition during
infection. In the case of influenza viruses, numerous reports have
demonstrated that loss of carbohydrates on HA can affect its
biological functions. For example, Deom et al.21 reported that
deletion of a complex oligosaccharide on the tip of the HA
would increase virus-cell interaction and make it easier for
the mutant viruses to survive in the infected cells. The increased
interaction between less-glycosylated HA and sialosides was
also demonstrated in our recent studies using sugar microar-
ray:17 the more outer glycans removed, the higher receptor
binding affinity and immunogeneity observed, leading to the
development of more potent HA vaccines with broader neu-
tralization activities.17 To further understand how individual
glycans of a full-length HA affect receptor binding, we report
here the expression of HA variants with a deleted glycosylation
Establishment of a Platform for Quantitative Analysis of
Sialosides Binding (KD Determination). Recombinant full-length
HAs with a C-terminal Strep-tag and a (His)6 tag were prepared
from human HEK293 cells for array detection. Strep-tag is an
eight-residue minimal peptide sequence with neutral charges
and exhibits intrinsic affinity toward streptavidin.30 The Strep-
tag was reported to not to hamper protein folding nor secretion
and it usually does not interfere with protein function.30 Prior
to analyze binding specificity of HA toward sialosides, a general
(12) Blixt, O.; et al. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17033–17038.
(13) Stevens, J.; Blixt, O.; Glaser, L.; Taubenberger, J. K.; Palese, P.;
Paulson, J. C.; Wilson, I. A. J. Mol. Biol. 2006, 355, 1143–1155.
(14) Stevens, J.; Blixt, O.; Chen, L.-M.; Donis, R. O.; Paulson, J. C.;
Wilson, I. A. J. Mol. Biol. 2008, 381, 1382–1394.
(15) Maines, T. R.; Jayaraman, A.; Belser, J. A.; Wadford, D. A.; Pappas,
C.; Zeng, H.; Gustin, K. M.; Pearce, M. B.; Viswanathan, K.; Shriver,
Z. H.; Raman, R.; Cox, N. J.; Sasisekharan, R.; Katz, J. M.; Tumpey,
T. M. Science 2009, 325, 484–487.
(16) Childs, R. A.; Palma, A. S.; Wharton, S.; Matrosovich, T.; Liu, Y.;
Chai, W.; Campanero-Rhodes, M. A.; Zhang, Y.; Eickmann, M.; Kiso,
M.; Hay, A.; Matrosovich, M.; Feizi, T. Nat. Biotechnol. 2009, 27,
797–799.
(22) Varki, A. Glycobiology 1993, 3, 97–130.
(23) Muthana, S.; Yu, H.; Cao, H.; Cheng, J.; Chen, X. J. Org. Chem.
2009, 74, 2928–2936.
(24) Koeller, K. M.; Wong, C. H. Nature 2001, 409, 232–240.
(25) Hsu, C. H.; Chu, K. C.; Lin, Y. S.; Han, J. L.; Peng, Y. S.; Ren,
C. T.; Wu, C. Y.; Wong, C. H. Chem.sEur. J. 2010, 16, 1754–60.
(26) Komba, S.; Galustian, C.; Ishida, H.; Feizi, T.; Kannagi, R.; Kiso, M.
Angew. Chem., Int. Ed. 1999, 38, 1131–1133.
(17) Wang, C. C.; Chen, J. R.; Tseng, Y. C.; Hsu, C. H.; Hung, Y. F.;
Chen, S. W.; Chen, C. M.; Khoo, K. H.; Cheng, T. J.; Cheng, Y. S.;
Jan, J. T.; Wu, C. Y.; Ma, C.; Wong, C. H. Proc. Natl. Acad. Sci.
U.S.A. 2009, 106, 18137–18142.
(18) Vinikoor, M.; Stevens, J.; Nawrocki, J.; Singh, K. J. Clin. Microbiol.
2009, 47, 3055.
(27) Komba, S.; Yamaguchi, M.; Ishida, H.; Kiso, M. Biol. Chem. 2001,
382, 233–240.
(19) de Boer, G. F.; Back, W.; Osterhaus, A. D. Arch. Virol. 1990, 115,
47–61.
(28) Yamaguchi, M.; Ishida, H.; Kanamori, A.; Kannagi, R.; Kiso, M.
J. Carbohydr. Chem. 2004, 23, 201–215.
(20) Skropeta, D. Bioorg. Med. Chem. 2009, 17, 2645–2653.
(21) Deom, C. M.; Caton, A. J.; Schulze, I. T. Proc. Natl. Acad. Sci. U.S.A.
1986, 83, 3771–3775.
(29) Stevens, J.; Corper, A. L.; Basler, C. F.; Taubenberger, J. K.; Palese,
P.; Wilson, I. A. Science 2004, 303, 1866–1870.
(30) Schmidt, T. G. M.; Skerra, A. Nature Protocols 2007, 2, 1528–1535.
9
14850 J. AM. CHEM. SOC. VOL. 132, NO. 42, 2010